Exploring the natural products chemical space through a molecular search to discover potential inhibitors that target the hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD)

Introduction: Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) enzymes are major therapeutic targets of anemia and ischemic/hypoxia diseases. To overcome safety issues, liver failure, and problems associated with on-/off-targets, natural products due to their novel and unique structure...

Full description

Saved in:

Bibliographic Details
Main Authors:	Abrar Mohammad Sayaf (Author), Saif Ullah Khalid (Author), Jawad Ahmed Hameed (Author), Abdulrahman Alshammari (Author), Abbas Khan (Author), Anwar Mohammad (Author), Saeed Alghamdi (Author), Dong-Qing Wei (Author), KarKheng Yeoh (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
by: Andrey A. Poloznikov, et al.
Published: (2021)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023)

Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism
by: Matthew Riopel, et al.
Published: (2020)

Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma
by: Muhammad Suleman, et al.
Published: (2022)

Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice
by: Shunji Nishide, et al.
Published: (2020)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
by: Jie Lun, et al.
Published: (2023)

Therapeutic Effect of Extracellular Vesicles Derived from HIF Prolyl Hydroxylase Domain Enzyme Inhibitor-Treated Cells on Renal Ischemia/Reperfusion Injury
by: Zhao-Ying Ding, et al.
Published: (2022)

Human prolyl hydroxylase expression in uterine leiomyoma during the menstrual cycle
by: Iwahashi Masaaki, et al.
Published: (2012)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
by: Amit A. Joharapurkar, et al.
Published: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022)

Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
by: Md. Aminul Islam, et al.
Published: (2023)

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD
by: Tetsuhiro Tanaka, et al.
Published: (2009)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
by: Jing Li, et al.
Published: (2022)

Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis
by: Qiong Huang, et al.
Published: (2023)

Structure-Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
by: Andrey A. Poloznikov, et al.
Published: (2022)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
by: Mengqiu Miao, et al.
Published: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
by: Yu-Hsiang Chou, et al.
Published: (2023)

Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
by: Helge Waldum
Published: (2023)

Pan-Cancer Analysis and Drug Formulation for GPR139 and GPR142
by: Aman Chandra Kaushik, et al.
Published: (2021)

Integrated PPI- and WGCNA-Retrieval of Hub Gene Signatures Shared Between Barrett's Esophagus and Esophageal Adenocarcinoma
by: Asma Sindhoo Nangraj, et al.
Published: (2020)

Thrombospondin-1 and prolyl 4-hydroxylase subunit alpha 3 as potential biomarkers of salivary gland fibrosis
by: Zijian Zhang, et al.
Published: (2023)

Efficacy of novel drugs hypoxia inducible factor prolyl hydroxylase inhibitor in therapy of posttransplant anemia. A review
by: Piotr Pawlowski, et al.
Published: (2024)

Exploring the medicinal potential of Dark Chemical Matters (DCM) to design promising inhibitors for PLpro of SARS-CoV-2 using molecular screening and simulation approaches
by: Abbas Khan, et al.
Published: (2023)

Ginsenosides ameliorates high altitude-induced hypoxia injury in lung and kidney tissues by regulating PHD2/HIF-1α/EPO signaling pathway
by: Peng Ji, et al.
Published: (2024)

Suppression of collagen IV alpha‐2 subunit by prolyl hydroxylase domain inhibition via hypoxia‐inducible factor‐1 in chronic kidney disease
by: Mohammad Sanaei‐Ardekani, et al.
Published: (2021)

Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats
by: Anqi Zhang, et al.
Published: (2021)

Prolyl-hydroxylase inhibitor-induced regeneration of alveolar bone and soft tissue in a mouse model of periodontitis through metabolic reprogramming
by: Elan Zebrowitz, et al.
Published: (2022)

Exploring the natural products chemical space to abrogate the F3L-dsRNA interface of monkeypox virus to enhance the immune responses using molecular screening and free energy calculations
by: Muhammad Suleman, et al.
Published: (2024)

Novel mutations in structural proteins of dengue virus genomes
by: Saira Mushtaq, et al.
Published: (2023)

Deep learning facilitates efficient optimization of antisense oligonucleotide drugs
by: Shenggeng Lin, et al.
Published: (2024)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023)

Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis
by: Song Ren, et al.
Published: (2024)

Proline hydroxylase 2 (PHD2) promotes brown adipose thermogenesis by enhancing the hydroxylation of UCP1
by: Fan Li, et al.
Published: (2023)

Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications
by: Tingting Fang, et al.
Published: (2023)

Traditional Chinese medicine: An important source for discovering candidate agents against hepatic fibrosis
by: Wen-Qing Li, et al.
Published: (2022)

Molecular screening of phytocompounds targeting the interface between influenza A NS1 and TRIM25 to enhance host immune responses
by: Muhammad Suleman, et al.
Published: (2024)

ceRNA regulatory network of FIH inhibitor as a radioprotector for gastrointestinal toxicity by activating the HIF-1 pathway
by: Yu-wei Yang, et al.
Published: (2021)

Prediction and associated factors of non-steroidal anti-inflammatory drugs efficacy in migraine treatment
by: Zhao-Xuan Lu, et al.
Published: (2022)

ATC-NLSP: Prediction of the Classes of Anatomical Therapeutic Chemicals Using a Network-Based Label Space Partition Method
by: Xiangeng Wang, et al.
Published: (2019)